EUCTR2007-000468-26-IT进行中（未招募）不适用
A phase I/II multicentre study to evaluate the safety and efficacy of rituximab (monoclonal antibody anti-CD20) for prevention and/or therapy of EBV-disease. - ND
OSPEDALE POLICLINICO S. MATTEO0 个研究点开始时间: 2007年5月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •age < 18; patients receiving stem cell transplantation or organ transplantation and patiets with primitive immunodeficiency
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •evidence of sistemic infection, known ipersensibilities to rituximab, ...
研究者
相似试验
进行中（未招募）
不适用
A Trial to assess the safety and efficacy of the medication Eltrombopag, indicated for patients with chronic lymphocytic leukemia along with low platelet counts who are planned to recieve a chemotherapy.EUCTR2010-023022-20-ATniversitätsklinikum Ulm82
进行中（未招募）
不适用
A Trial to assess the safety and efficacy of the medication Eltrombopag, indicated for patients with chronic lymphocytic leukemia along with low platelet counts who are planned to recieve a chemotherapy.CLL patients with thrombocytopenia and indication for chemotherapeutic treatment with alkylating agents and/or purine analoguesMedDRA version: 15.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 15.1Level: LLTClassification code 10068919Term: B-cell chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2010-023022-20-DEniversitätsklinikum Ulm82
招募中
1 期
Gallium Imaging Pilot Study in Metastatic MelanomaMetastatic MelanomaLocally Advanced MelanomaCancer - Malignant melanomaACTRN12624000085572Alpha-9 Theranostics Australia Pty Ltd30
进行中（未招募）
1 期
Clinical phase 2/3 study to investigate the safety and efficacy of Blinatumomab in subjects with Non Hodgkin Lymphoma that did not respond to previous therapy or that relapsed after initially successful previous therapyEUCTR2016-002044-16-BEAmgen Inc.332
进行中（未招募）
1 期
Clinical phase 2/3 study to investigate the safety and efficacy of Blinatumomab in subjects with Non Hodgkin Lymphoma that did not respond to previous therapy or that relapsed after initially successful previous therapySubjects with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL)MedDRA version: 20.0Level: PTClassification code 10020067Term: High grade B-cell lymphoma Burkitt-like lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10036710Term: Primary mediastinal large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10063908Term: Non-Hodgkin's lymphoma unspecified histology aggressiveSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002044-16-GBAmgen Inc.332